18694-40-1 Usage
Description
Epirizole is a non-acidic analgesic and anti-inflammatory agent that has been found to induce precocious differentiation of insulin-producing ti-cells in larval zebrafish and increase the expression of MDR1 mRNA in Caco-2 cells.
Uses
Used in Pharmaceutical Industry:
Epirizole is used as an analgesic and anti-inflammatory agent for its ability to relieve pain and reduce inflammation without causing acidity.
Used in Diabetes Research:
Epirizole is used as a research compound for its potential role in inducing the differentiation of insulin-producing ti-cells in larval zebrafish, which may have implications for the development of new treatments for diabetes.
Used in Pharmaceutical Research:
Epirizole is used as a research compound for its ability to increase the expression of MDR1 mRNA in Caco-2 cells, which may have potential applications in the development of new drugs and drug delivery systems.
Originator
Mebron,Daiichi Seiyaku,Japan,1970
Manufacturing Process
A mixture of 16.3 g of 4-methyl-6-methoxy-2-pyrimidinyl-hydrazine,13.7 g of
ethyl acetoacetate and 16.3 ml of methanol was refluxed 2 hours on a water
bath. After a mixture of 4.7 g of sodium hydroxide, 4.7 ml of water and 27 ml
of methanol was added dropwise thereto at about 50°C, the reaction mixture
was refluxed for 2 hours more, then methanol was distilled off and the residue
was dissolved in 130 ml of water. The solution was adjusted to pH 6 with
acetic acid. The precipitate was filtered, washed with water and dried to give
24 g (yield: 95.3%) of crystals, MP 97° to 98°C. Recrystallization from ligroin
gave 1-(4'-methyl-6'-methoxy-2'-pyrimidinyl)-3-methyl-3-pyrazoline-5-one,
MP 102° to 103°C.To a solution of 4.76 g of 1-( 4'-methyl-6'-methoxy-2'-pyrimidinyl)-3-methyl-
3-pyrazoline 5-one in 200 ml of ether was added an ether solution containing
6 molar equivalents of diazomethane and the reaction mixture was allowed to
stand at room temperature for 20 hours. After distilling off the solvent, the
residue was dissolved in 160 ml of water, made alkaline (pH 10) with sodium
hydroxide solution and extracted three times with 140 ml of benzene. The
extract was washed with a small amount of water, dried over sodium sulfate
and evaporated to give a crystalline mass. Recrystallization from
isopropylether gave 1-(4'-methyl-6'-methoxy-2'-pyrimidinyl)-3-methyl-5-
methoxypyrazole (3.96 g, 84%) as color less prisms, MP 90° to 92°C.
Therapeutic Function
Antiinflammatory, Analgesic, Antipyretic
Check Digit Verification of cas no
The CAS Registry Mumber 18694-40-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,6,9 and 4 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 18694-40:
(7*1)+(6*8)+(5*6)+(4*9)+(3*4)+(2*4)+(1*0)=141
141 % 10 = 1
So 18694-40-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N4O2/c1-7-6-9(16-3)14(13-7)10-11-5-4-8(12-10)15-2/h4-6H,1-3H3
18694-40-1Relevant articles and documents
Synthesis and crystal structure of (p-CH3C6H4NH3)6P6O18·8H2O
Nasr, C. Ben,Rzaigui
, p. 557 - 569 (2008/10/08)
Preparation and complete structural characterization by X-ray diffraction (XRD), IR absorption, thermogravimetric and differential thermal analysis (TG-DTA), and mass angle spinning (MAS) NMR spectroscopy are given for a new cyclohexaphosphate, (p-CH3C6H4NH3)6P6O18·8H2O. This compound is monoclinic in space group P21/c, with Z = 2 and unit-cell parameters a = 10.695(6), b = 24.952(8), c = 11.163(4) angstrom, and β = 97.53(4)°. The crystal structure was solved and refined down to R = 0.036, using 4168 independent reflections. The atomic arrangement can be described as layer organization. Layers built by P6O18 ring anions and water molecules spread parallel to the plane (010). Between these layers are located the organic groups that form hydrogen bonds with P6O18 ring oxygens. Geometrical characteristics of the hydrogen bonds are described.
Synthesis and crystal structure of (o-CH3C6H4NH3)6P6O18*2H2O
Larafa, K.,Mahjoub, A.,Rzaigui, M.,Durif, A.
, (2008/10/08)
(o-CH3C6H4NH3)6P6O18*2H2O is triclinic, P1-, with Z = 1 and the following unit-cell dimensions: a = 10.395(4), b = 10.793(5), c = 13.839(4)?, alpha. = 103.98(3), β = 91.62(3), γ = 116.65(3)° Itscrystal structure has been determined and refined down to R = 0.036, us ing 5850 independent reflections. Among the three crystallographically independent CH3-C6H4-NH3 groups one is disordered. All the H-atoms belonging to the nondisorderd ligands have been located and refined. The hydrogen-bond distribution is carefully described.
Structural characterization of a series of cyclohexaphosphates: Ca2M2P6O18 · 6H2O (M = K, Tl, Rb)
Abid,Rzaigui
, p. 308 - 313 (2008/10/08)
Three new cyclohexaphosphates with the general formula Ca2M2P6O18 · 6H2O (M = K, Tl, Rb) are reported. They crystallize with monoclinic unit cells and are isotopic. As an example the paramters of Ca2K2P6O18 · 6H2O are a = 7.266(1), b = 11.833(2), c = 12.300(2) A, β = 103.17(1)0, Z = 2, P21In, V = 1030(3) A3, and Dx = 2.387 g cm-3. Crystal structure of this phase was determined using 6292 independent reflections with a final R = 0.025. The atomic arrangement can be described as puckered layers containing water bonded P6O18 anions and Ca2+ and K+ cations, alternating along the (1, 0, 1) direction. Synthesis and characterization by X-ray diffraction, IR absorption, and TA are described.